Advisory Committee on Immunization Practices (ACIP), 8427 [2017-01624]

Download as PDF Federal Register / Vol. 82, No. 15 / Wednesday, January 25, 2017 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of application in response to Funding Opportunity Announcement (FOA) PAR 15–303, Occupational Safety and Health Education and Research Centers (ERC). Times and Dates: 8:00 a.m.–6:00 p.m., EST, February 22, 2017 (Closed), 8:00 a.m.–6:00 p.m., EST, February 23, 2017 (Closed), 8:00 a.m.–6:00 p.m., EST, February 24, 2017 (Closed). Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, Virginia 22314, Telephone: (703) 837–0440. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Occupational Safety and Health Education and Research Centers (ERC)’’, PAR 15–303. Contact Person for More Information: Michael Goldcamp, Ph.D., Scientific Review Officer, CDC, 1095 Willowdale Road, Morg Building H, Room 1806, Mailstop 1808, Morgantown, West Virginia, Telephone: (304) 285–5951, EHG8@CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–01628 Filed 1–24–17; 8:45 am] BILLING CODE 4163–18–P mstockstill on DSK3G9T082PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) In accordance with section 10(a)(2) of the Federal Advisory Committee Act VerDate Sep<11>2014 20:29 Jan 24, 2017 Jkt 241001 (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee. Times and Dates: 8:00 a.m.–5:40 p.m., EST, February 22, 2017; 8:00 a.m.–1:00 p.m., EST, February 23, 2017. Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent ‘‘Oz’’ Nelson Auditorium, Atlanta, Georgia 30329. Status: Open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt February 13, 2017. All requests must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one single-spaced typed page in length and delivered in 3 minutes or less. Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Written comments received in advance of the meeting will be included in the official record of the meeting. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: http:// www.cdc.gov/vaccines/acip/index.html. Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans. Matters for Discussion: The agenda will include discussions on: Meningococcal vaccine; influenza; hepatitis B vaccine; herpes zoster vaccine; vaccine safety; yellow fever vaccine; Zika virus vaccine; mumps PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 8427 outbreak; Dengue virus vaccines; Polio Eradication Initiative; Measles and Rubella Elimination Initiative; adult immunization and vaccine supply. A recommendation vote is scheduled for hepatitis B vaccine and influenza. A Vaccines for Children (VFC) vote is scheduled for hepatitis B vaccine. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Stephanie Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30329, telephone 404/ 639–8836; Email ACIP@CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–01624 Filed 1–24–17; 8:45 am] BILLING CODE 4160–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA), RFA–CE–12–0010501SUPP16, Grants for Injury Prevention and Control. Times and Dates: 8:00 a.m.–5:00 p.m., EST, February 21–22, 2017 (Closed). Place: The Georgian Terrace, 659 Peachtree Street NE., Atlanta, GA 30308. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to E:\FR\FM\25JAN1.SGM 25JAN1

Agencies

[Federal Register Volume 82, Number 15 (Wednesday, January 25, 2017)]
[Notices]
[Page 8427]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-01624]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices (ACIP)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announce the following meeting of the aforementioned 
committee.
    Times and Dates: 8:00 a.m.-5:40 p.m., EST, February 22, 2017; 8:00 
a.m.-1:00 p.m., EST, February 23, 2017.
    Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton 
Road NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia 
30329.
    Status: Open to the public, limited only by the space available. 
Time will be available for public comment. The public is welcome to 
submit written comments in advance of the meeting. Comments should be 
submitted in writing by email to the contact person listed below. The 
deadline for receipt February 13, 2017. All requests must contain the 
name, address, and organizational affiliation of the speaker, as well 
as the topic being addressed. Written comments should not exceed one 
single-spaced typed page in length and delivered in 3 minutes or less. 
Please note that the public comment period may end before the time 
indicated, following the last call for comments. Members of the public 
who wish to provide public comments should plan to attend the public 
comment session at the start time listed. Written comments received in 
advance of the meeting will be included in the official record of the 
meeting.
    The meeting will be webcast live via the World Wide Web; for 
instructions and more information on ACIP please visit the ACIP Web 
site: http://www.cdc.gov/vaccines/acip/index.html.
    Purpose: The committee is charged with advising the Director, CDC, 
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, 
the committee is mandated to establish and periodically review and, as 
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program, 
along with schedules regarding dosing interval, dosage, and 
contraindications to administration of vaccines. Further, under 
provisions of the Affordable Care Act, section 2713 of the Public 
Health Service Act, immunization recommendations of the ACIP that have 
been approved by the Director of the Centers for Disease Control and 
Prevention and appear on CDC immunization schedules must be covered by 
applicable health plans.
    Matters for Discussion: The agenda will include discussions on: 
Meningococcal vaccine; influenza; hepatitis B vaccine; herpes zoster 
vaccine; vaccine safety; yellow fever vaccine; Zika virus vaccine; 
mumps outbreak; Dengue virus vaccines; Polio Eradication Initiative; 
Measles and Rubella Elimination Initiative; adult immunization and 
vaccine supply. A recommendation vote is scheduled for hepatitis B 
vaccine and influenza. A Vaccines for Children (VFC) vote is scheduled 
for hepatitis B vaccine.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Stephanie Thomas, National 
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton 
Road NE., MS-A27, Atlanta, Georgia 30329, telephone 404/639-8836; Email 
ACIP@CDC.GOV.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both the Centers for Disease Control and Prevention and the Agency for 
Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-01624 Filed 1-24-17; 8:45 am]
 BILLING CODE 4160-18-P